ConexiantExperts Prioritize 3 Drugs for Alzheimer’s

A 23-expert international consensus selected three existing agents for priority Alzheimer’s trials based on mechanistic plausibility, preclinical efficacy, and tolerability in older adults.

🔬 Clinical Considerations

• Live attenuated herpes zoster vaccine (Zostavax) ranked first by lay advisors; a 941,000-patient systematic review estimated 16% relative reduction in incident dementia, with a UK natural experiment showing 20% relative reduction and 3.5 percentage point absolute reduction
• Sildenafil’s proposed AD mechanisms include tau hyperphosphorylation reduction, amyloid-beta-42 lowering, and cerebral hemodynamic improvement; two large insurance claims analyses suggested lower AD risk, but a Medicare study found no association
• Riluzole preserved brain glucose metabolism in a 6-month Phase 2a trial (n=50), with strongest signal in posterior cingulate cortex; no cognitive outcome data yet available
• All three candidates lack Phase 3 RCT data in AD; clinical evidence remains observational or early-phase only

🎯 Practice Applications

• Prioritize herpes zoster vaccination in at-risk older patients given converging epidemiologic evidence linking vaccination to reduced dementia incidence
• Discuss the repurposing trial pipeline with patients asking about emerging Alzheimer’s prevention strategies
• Monitor the PROTECT platform trial announcements for Phase 2b/3 enrollment opportunities across all three candidates

More on Alzheimer’s/Dementia